베니텍 바이오파마(BNTC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $11.02 (-2.99%), 시가총액 $0.37B, 52주 최저~최고 $10.06 ~ $16.56.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, Califor
베니텍 바이오파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
베니텍 바이오파마의 현재 주가는 $11.02 (-2.99%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
베니텍 바이오파마의 시가총액은 약 $0.37B입니다.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA int